Prime Minister Moustafa Madbouli reviewed on Tuesday a development plan for Egypt’s state-owned Holding Company for Pharmaceuticals (HoldiPharma) and its subsidiaries, as the government seeks to strengthen the performance of public-sector drug manufacturers.
The meeting brought together senior government officials and executives from the HoldiPharma.
Madbouli stressed that Egypt is pursuing plans to localize pharmaceutical production, transfer technology, and strengthen national manufacturing capabilities. The government, he added, views the sector as a key pillar of economic development.
During the meeting, company officials outlined a strategy aimed at transforming the holding company into a globally competitive healthcare player.
The company operates a network of factories that manufacture a wide range of products, including tablets, capsules, injectables, medical solutions, inhalers, eye drops, ointments, and dental anesthetics. It also manufactures products for several international pharmaceutical companies.
The company’s development plan focuses on producing high-quality pharmaceutical products, adopting advanced technologies, expanding research and development activities, and launching innovative medicines.
It also includes upgrading facilities to meet international Good Manufacturing Practice (GMP) standards and the requirements of both the World Health Organization and the Egyptian Drug Authority. Recent investments have covered water treatment stations, production lines, laboratories, storage facilities, and employee training programmes.
The company also plans to expand its product portfolio in response to market demand, particularly in areas such as antibiotics, cardiovascular treatments, diabetes medications, blood thinners, and therapies for chronic heart failure.
A major focus of the strategy is boosting exports through a broader product range, new distribution partnerships, and targeted market-entry plans. The company is also seeking to strengthen cooperation with the private sector and improve human capital development.
Madbouli described the plan as ambitious and pledged continued government support, saying the pharmaceutical holding company has significant opportunities for growth and higher returns.
